Ann Arbor, MINCT00360646Now EnrollingIRB Ready

Drug Induced Liver Injury Clinical Trial in Ann Arbor, MI

Access cutting-edge drug induced liver injury treatment through this clinical trial at a research site in Ann Arbor. Study-provided care at no cost to qualified participants.

Sponsored by Duke University

Quick Self-Assessment

See if you qualify for this Ann Arbor location

Preparing your pre-screening questions…

Expert Care in Ann Arbor

Access drug induced liver injury specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related drug induced liver injury treatment provided free

Apply for This Ann Arbor Location

Check if you qualify for this drug induced liver injury clinical trial in Ann Arbor, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Ann Arbor

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Ann Arbor site if eligible
  4. 4Begin participation

About This Drug Induced Liver Injury Study in Ann Arbor

The purpose of this study is to establish retrospectively a nationwide registry of patients who have suffered drug-induced liver injury (DILI), and to collect, immortalize, and store serum, DNA, and lymphocytes from these patients. ILIAD will serve as a resource for subsequent mechanistic investigations into the basis of severe idiosyncratic DILI. The primary goal of the ILIAD protocol is to create: (a) a clinical database consisting of individuals who have experienced severe DILI and the relevant clinical data concerning the episode of DILI; and, (b) to create a bank of biological specimens obtained from these individuals. These biological specimens will be DNA, plasma, and immortalized lymphocytes. Immortalized lymphocytes will provide unlimited amounts of genomic DNA for study as well as living immune cells for phenotyping studies. A secondary goal of the ILIAD protocol is to maintain a registry of cases in the ILIAD database so that they may be recontacted in the future. It is expected that this will facilitate additional studies exploring the mechanisms of DILI.

Sponsor: Duke University

Who Can Participate

Inclusion Criteria

Screening Criteria To be included in the ILIAD registry, the following criteria must be satisfied:
The treating gastroenterologist / hepatologist or health care professional must believe that the subject suffered drug-induced liver injury;
The subject must be alive and the date of onset of the qualifying DILI episode must have occurred on or after January 1, 1994;
Evidence of injury that is known or suspected to be related to consumption of a drug or HDS/CAM product
The subject is taking only one of these drugs or HDS agent(s) in the period leading up to the onset of the qualifying DILI episode;
Have clinically important DILI defined in terms of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (Alk Phos).
Sufficient documentation of the event for the Causality Committee to make a determination.

Exclusion Criteria

Subjects will be excluded according to the following criteria:
are not willing to have medical information and blood samples taken;
are unable to adequately give informed consent to participate in the study including the blood draw for the genetic component;
age \< 2 years old at the time of study enrollment (due to blood volume requirements).
Have a competing cause of liver injury such as hepatic ischemia that the investigator felt to be the primary reason for the observed liver injury. Known, pre-existing autoimmune hepatitis; primary biliary cirrhosis, primary sclerosing cholangitis, or other chronic biliary tract disease. Subjects are excluded due to acetaminophen hepatoxicity or liver transplant or allogeneic bone marrow transplant prior to development of drug-CAM induced liver injury.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Ann Arbor?

Yes, this clinical trial (NCT00360646) has an active research site in Ann Arbor, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Drug Induced Liver Injury Treatment Options in Ann Arbor, MI

If you're searching for drug induced liver injury treatment options in Ann Arbor, MI, this clinical trial (NCT00360646) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Ann Arbor research site is actively enrolling participants for this clinical trial. You'll receive care from experienced drug induced liver injury specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all drug induced liver injury clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Ann Arbor, MI

See all ulcerative colitis clinical trials recruiting in Ann Arbor — not just this study.

Browse Ulcerative Colitis Trials in Ann Arbor →

Browse More Trials by Condition

Ulcerative Colitis TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Ann Arbor?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Ann Arbor, MI